Company Xintela AB (publ) Nasdaq Stockholm
Equities
SE0007756903
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Stem Cell Therapies
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 67 | 08-12-31 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 12-12-31 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 17-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 20-12-31 |
Chairman | 67 | 10-12-31 | |
Director/Board Member | 64 | 21-12-31 | |
Director/Board Member | 61 | 20-12-31 | |
Director/Board Member | 62 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 567,006,473 | 177,368,068 ( 31.28 %) | 0 | 31.28 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. |
Biotechnology
|
Sector
1st Jan change | Capi. | |
---|---|---|
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |